AK-006 is under clinical development by Allakos and currently in Phase I for Chronic Urticaria Or Hives. According to GlobalData, Phase I drugs for Chronic Urticaria Or Hives have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AK-006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AK-006 is under development for the treatment of inflammatory diseases such as systemic anaphylaxis, chronic spontaneous urticaria (CSU) and contact dermatitis. The drug candidate is a humanized IgG1 monoclonal antibody and acts by targeting SIGLEC6. It is administered through intravenous and subcutaneous route.
Allakos is a clinical-stage biotechnology company that develops antibodies that target immunomodulatory receptors present on immune effector cells. The company investigates the therapeutic areas of eosinophilic gastrointestinal diseases, chronic inflammatory diseases with continuing gastrointestinal symptoms along with an increase in the count of mast cells in the body. Its product offerings include AK002, an antibody that targets Siglec-8, an inhibitory receptor for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic and mastocytosis. The company is discovering AK007 to treat immuno-oncology disease. It partners with universities ad pharmaceutical companies. Allakos is headquartered in Redwood City, California, the US.
For a complete picture of AK-006’s drug-specific PTSR and LoA scores, buy the report here.